FDA Adds Fasenra Indication for Severe Asthma in Children
Indication is for add-on maintenance treatment of children aged 6 to 11 years with severe eosinophilic asthma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.